ArQule, Inc. (NASDAQ:ARQL)
CAPS Rating:
A clinical-stage biotechnology company, engaged in the research and development of cancer therapeutics. Its mission is to research, develop and commercialize targeted cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics.
RSS Headlines
Fool UK
Recs
If the next phase of clinical trials goes well. This company will be set for the remainder of its life. Worth a look